Adaptimmune Therapeutics ADAP Stock
Adaptimmune Therapeutics Price Chart
Adaptimmune Therapeutics ADAP Financial and Trading Overview
| Adaptimmune Therapeutics stock price | 0.25 USD |
| Previous Close | 0.5 USD |
| Open | 0.5 USD |
| Bid | 0 USD x 4000 |
| Ask | 0 USD x 900 |
| Day's Range | 0.49 - 0.53 USD |
| 52 Week Range | 0.42 - 2.35 USD |
| Volume | 341.05K USD |
| Avg. Volume | 428.83K USD |
| Market Cap | 112.33M USD |
| Beta (5Y Monthly) | 1.945 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.6 USD |
ADAP Valuation Measures
| Enterprise Value | 537.88M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.8832143 |
| PEG Ratio (5 yr expected) | -1.14 |
| Price/Sales (ttm) | 1.5804404 |
| Price/Book (mrq) | 1.2747422 |
| Enterprise Value/Revenue | 7.567 |
| Enterprise Value/EBITDA | -5.136 |
Trading Information
Adaptimmune Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.945 |
| 52-Week Change | N/A |
| S&P500 52-Week Change | N/A |
| 52 Week High | 2.35 USD |
| 52 Week Low | 0.42 USD |
| 50-Day Moving Average | 0.57 USD |
| 200-Day Moving Average | 0.93 USD |
ADAP Share Statistics
| Avg. Volume (3 month) | 428.83K USD |
| Avg. Daily Volume (10-Days) | 438.73K USD |
| Shares Outstanding | 227.12M |
| Float | 1.01B |
| Short Ratio | 15.62 |
| % Held by Insiders | 0.30% |
| % Held by Institutions | 66.53% |
| Shares Short | 6.17M |
| Short % of Float | 5.74% |
| Short % of Shares Outstanding | 2.71% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | September 30, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -133.94% |
| Operating Margin (ttm) | -637.14% |
| Gross Margin | -79.69% |
| EBITDA Margin | -147.33% |
Management Effectiveness
| Return on Assets (ttm) | -22.48% |
| Return on Equity (ttm) | -94.51% |
Income Statement
| Revenue (ttm) | 71.08M USD |
| Revenue Per Share (ttm) | 0.38 USD |
| Quarterly Revenue Growth (yoy) | 4.50% |
| Gross Profit (ttm) | -100578000 USD |
| EBITDA | -104721000 USD |
| Net Income Avi to Common (ttm) | -95204000 USD |
| Diluted EPS (ttm) | -0.54 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 161.73M USD |
| Total Cash Per Share (mrq) | 0.12 USD |
| Total Debt (mrq) | 25.6M USD |
| Total Debt/Equity (mrq) | 29.05 USD |
| Current Ratio (mrq) | 2.919 |
| Book Value Per Share (mrq) | 0.388 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -124162000 USD |
| Levered Free Cash Flow (ttm) | -43849376 USD |
Profile of Adaptimmune Therapeutics
| Country | United States |
| State | N/A |
| City | Abingdon |
| Address | 60 Jubilee Avenue |
| ZIP | OX14 4RX |
| Phone | 44 12 3543 0000 |
| Website | https://www.adaptimmune.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 534 |
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; co-development collaboration agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Q&A For Adaptimmune Therapeutics Stock
What is a current ADAP stock price?
Adaptimmune Therapeutics ADAP stock price today per share is 0.25 USD.
How to purchase Adaptimmune Therapeutics stock?
You can buy ADAP shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Adaptimmune Therapeutics?
The stock symbol or ticker of Adaptimmune Therapeutics is ADAP.
Which industry does the Adaptimmune Therapeutics company belong to?
The Adaptimmune Therapeutics industry is Biotechnology.
How many shares does Adaptimmune Therapeutics have in circulation?
The max supply of Adaptimmune Therapeutics shares is 257.23M.
What is Adaptimmune Therapeutics Price to Earnings Ratio (PE Ratio)?
Adaptimmune Therapeutics PE Ratio is now.
What was Adaptimmune Therapeutics earnings per share over the trailing 12 months (TTM)?
Adaptimmune Therapeutics EPS is -0.3 USD over the trailing 12 months.
Which sector does the Adaptimmune Therapeutics company belong to?
The Adaptimmune Therapeutics sector is Healthcare.
Adaptimmune Therapeutics ADAP included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17449.89 USD — |
+0.87
|
6.97B USD — | 17149.36 USD — | 17506.58 USD — | — - | 6.97B USD — |
| NASDAQ Global Select Market Com NQGS | 8541.08 USD — |
+0.91
|
— — | 8392.44 USD — | 8567.09 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4132.89 USD — |
-2.63
|
— — | 4122.19 USD — | 4247.3 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 929.13 USD — |
-1.85
|
— — | 925.14 USD — | 947.12 USD — | — - | — — |
| NASDAQ Composite Total Return I XCMP | 21356.17 USD — |
+0.87
|
— — | 20988.36 USD — | 21425.55 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4486.38 USD — |
-0.37
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
- {{ link.label }} {{link}}